热线电话: 021-34661275
产品分类/PRODUCT CLASSIFICATION

上海细胞库

人源细胞系| 稳转细胞系| 基因敲除株| 基因点突变细胞株| 基因过表达细胞株| 重组细胞系| 猪的细胞系| 马细胞系| 兔的细胞系| 犬的细胞系| 山羊的细胞系| 鱼的细胞系| 猴的细胞系| 仓鼠的细胞系| 狗的细胞系| 牛的细胞| 大鼠细胞系| 小鼠细胞系| 其他细胞系|

原代细胞

原代细胞| 永生化细胞|

细胞培养

血清| 无血清冻存| 细胞培养试剂盒| 普通培养基| 完全培养基| 细胞污染预防| 细胞污染清除| 细胞培养辅助试剂|

细胞服务

STR鉴定服务| ATCC代购服务|

酶联试剂盒

人ELISA试剂盒| 大鼠ELISA试剂盒| 小鼠ELISA试剂盒| 兔ELISA试剂盒| 猪ELISA试剂盒| 鱼ELISA试剂盒| 牛ELISA试剂盒| 犬ELISA试剂盒| 鸭ELISA试剂盒| 豚鼠ELISA试剂盒| 鸡ELISA试剂盒| 绵羊ELISA试剂盒| 山羊ELISA试剂盒| 仓鼠ELISA试剂盒| 植物ELISA试剂盒| 药残留类试剂盒| 其他ELISA试剂盒|

生化试剂盒

生化试剂盒| 微量法检测盒| 分光法检测盒| 胶体金检测盒|

PCR试剂盒

荧光探针PCR试剂盒| 染料荧光PCR试剂盒| 核酸扩增/纯化| 普通PCR检测试剂盒| 质粒菌种感受态|

抗体蛋白

蛋白多肽| 抗体| 免疫组化| 免疫球蛋白|

试剂耗材

标准试液| 科研试剂| 缓 冲 液| 实验耗材| 高效液相色谱对照品|

首页 > 抗体蛋白 > 抗体
PE anti-human CD274 (B7-H1, PD-L1) Antibody
产品名称：
PE anti-human CD274 (B7-H1, PD-L1) Antibody
产品类别：
抗体
产品编号：
329705
产品应用：
329705
[价格]
规格 价格 库存
25tests ￥ 1416 1

产品详情

Product Details

Verified Reactivity
Human
Reported Reactivity
African Green, Baboon, Cynomolgus, Rhesus
Antibody Type
Monoclonal
Host Species
Mouse
Immunogen
Full length human PD-L1
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA)
Preparation
The antibody was purified by affinity chromatography, and conjugated with PE under optimal conditions.
Concentration
Lot-specific (to obtain lot-specific concentration, please enter the lot number in our Concentration and Expiration Lookup or Certificate of Analysis online tools.)
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 ?l per million cells in 100 ?l staining volume or 5 ?l per 100 ?l of whole blood.

Excitation Laser
Blue Laser (488 nm)
Green Laser (532 nm)/Yellow-Green Laser (561 nm)
Application Notes

Clone 29E.2A3 is reported to recognize an epitope on PD-L1 within the PD-L1-CD80 binding region5.?Additional reported applications (for the relevant formats) include: blocking1-3 and immunohistochemical staining of acetone-fixed frozen sections1.?The Ultra-LEAF? purified antibody (Endotoxin < 0.01 EU/?g, Azide-Free, 0.2 ?m filtered) is recommended for functional assays (Cat. No. 329715, 329716, 329745 - 329748).?

It has been observed that clone 29E.2A3 is able to bind to Alexa Fluor? 700 antibody conjugates during multi-color immunofluorescent staining. This interaction can be resolved by sequentially staining with the 29E.2A3 antibody first and then followed by the?Alexa Fluor? 700?conjugate of interest.

Clone 29E.2A3 does not work in Western blot applications7.

Application References

(PubMed link indicates BioLegend citation)
  1. Brown J, et al. 2003. J. Immunol. 170:1257. (FC, IHC, Block)
  2. Radziewicz H, et al. 2007. J. Virol. 81:2545. (Block)
  3. Nakamoto N, et al. 2009. PLoS Pathog. 5:e1000313. (Block)
  4. Barsoum IB, et al. 2014. Cancer Res. 74:665. PubMed
  5. Haile, S et al. 2013. J. Immunol. 191:2829.
  6. RL M, et al. 2015. PNAS. 112:6506-6514. PubMed
  7. Mahoney KM, et al. 2015. Cancer Immunol. Res. 3:1308.
Product Citations
  1. Soday L, et al. 2021. Frontiers in Immunology. 12:600056. PubMed
  2. Jiang G, et al. 2020. Aging (Albany NY). 12:11466. PubMed
  3. Shao L, et al. 2021. Cell Death Discov. 7:145. PubMed
  4. Cui J, et al. 2022. Cancer Cell Int. 22:72. PubMed
  5. Oreskovic E, et al. 2022. Proc Natl Acad Sci U S A. 119:. PubMed
  6. Schott DS, et al. 2017. Oncotarget. 8:72755. PubMed
  7. Roberts A, et al. 2021. Sci Rep. 11:4030. PubMed
  8. Katsurahara K, et al. 2021. Cancer Sci. 112:1026. PubMed
  9. Geuijen C, et al. 2021. Nat Commun. 12:4445. PubMed
  10. Kagoya Y, et al. 2018. Nat Commun. 9:1915. PubMed
  11. Sucker A, et al. 2017. Nat Commun. 8:15440. PubMed
  12. Huang X, et al. 2021. Nat Nanotechnol. 16:214. PubMed
  13. Zhang H, et al. 2021. Cancer Gene Ther. Online ahead of print. PubMed
  14. Jarosch S, et al. 2022. STAR Protoc. 3:101374. PubMed
  15. Sugawara E, et al. 2020. Autophagy. 1.323611111. PubMed
  16. Rosskopf S, et al. 2016. Sci Rep. 6:31580. PubMed
  17. Liu Y, et al. 2021. Oncogene. 40:2230. PubMed
  18. Fujiwara Y, et al. 2021. Pancreas. 50:405. PubMed
  19. Yi K, et al. 2022. Front Immunol. 12:802795. PubMed
  20. Mineo M, et al. 2020. Molecular Cell. 78(6):1207-1223.e8. PubMed
  21. Guan H, et al. 2016. Sci Rep. 6:35651. PubMed
  22. Tran L, et al. 2017. Cancer Immunol Res. 5:1141. PubMed
  23. Nduom E, et al. 2016. Neuro Oncology. 18: 195 - 205. PubMed
  24. Lin JR et al. 2018. eLife. 7 pii: e31657. PubMed
  25. Zong Z, et al. 2019. Front Immunol. 10:1643. PubMed
  26. Herter JM, et al. 2022. Strahlenther Onkol. Online ahead of print. PubMed
  27. Jutz S, et al. 2016. J Immunol Methods. 430:10-20. PubMed
  28. Bryson BD, et al. 2019. Nat Commun. 10:2329. PubMed
  29. Lee JM, et al. 2022. Lupus Sci Med. 9:. PubMed
  30. Leonard NA, et al. 2021. Cancers (Basel). 13:. PubMed
  31. Fan Z, et al. 2020. EMBO Mol Med. 12:e11571. PubMed
  32. Rolfes V, et al. 2018. Oncotarget. 9:27460. PubMed
  33. Souriant S, et al. 2019. Cell Rep. 26:3586. PubMed
  34. Wu Y, et al. 2021. Nat Commun. 12:2346. PubMed
  35. Wang Y, et al. 2021. Front Immunol. 12:654463. PubMed
  36. El Ahanidi H, et al. 2022. Front Oncol. 11:795242. PubMed
  37. Jarosch S, et al. 2021. Cell Rep Methods. 1:100104. PubMed
  38. Mao R, et al. 2020. Cancer Sci. 111:3174. PubMed
  39. Durand-Panteix S, et al. 2012. J Immunol. 189:181. PubMed
  40. Wu L, et al. 2018. Oncol Lett. 15:9507. PubMed
  41. Hu H, et al. 2022. Exp Ther Med. 24:487. PubMed
  42. Zhang R, et al. 2021. Front Oncol. 10:581733. PubMed
  43. Li H, et al. 2021. Adv Sci (Weinh). 2001596:8. PubMed
  44. Ye LL, et al. 2020. Annals of Translational Medicine. 8(24):1647. PubMed
  45. Su S et al. 2018. Cell. 175(2):442-457 . PubMed
  46. Bouleau A, et al. 2022. J Nucl Med. 63:1259. PubMed
  47. Pathania AS, et al. 2022. Mol Ther Oncolytics. 25:308. PubMed
  48. Houtsma R, et al. 2021. STAR Protoc. 2:100864. PubMed
  49. Okita R, et al. 2021. Thorac Cancer. 12:775. PubMed
  50. Iwasa M, et al. 2019. Oncotarget. 10:1903. PubMed
  51. Richardson JR, et al. 2018. Front Immunol. 2.182638889. PubMed
  52. Yoshino H, et al. 2021. Curr Issues Mol Biol. 43:153. PubMed
  53. Rydyznski Moderbacher C, et al. 2020. Cell. 183(4):996-1012.e19. PubMed
  54. Kim DH, et al. 2019. Exp Mol Med. 51:94. PubMed
  55. Zhao Y et al. 2018. Cell reports. 24(2):379-390 . PubMed
  56. Curnock AP, et al. 2021. JCI Insight. 6:. PubMed
  57. Dan J, et al. 2016. J Immunol. 197: 983 - 993. PubMed
  58. Lundell A, et al. 2017. Sci Rep. 7:39904. PubMed
  59. Park JA, et al. 2020. J Hematol Oncol. 0.661111111. PubMed
  60. Kwak T, et al. 2020. Cell Reports. 33(13):108571. PubMed
  61. Zhou C, et al. 2021. Mol Ther. 29:1512. PubMed
  62. Ahn A, et al. 2021. Cancers (Basel). 13:. PubMed
  63. Tsuchiya K, et al. 2021. Oncoimmunology. 10:1962656. PubMed
  64. Wang J, et al. 2022. Clin Transl Med. 12:e718. PubMed
  65. Rydyznski Moderbacher C, et al. 2022. J Clin Invest. :. PubMed
  66. Guo Q, et al. 2022. Blood Adv. 6:5668. PubMed
  67. Zhang Z, et al. 2022. Clin Transl Med. 12:e1072. PubMed
  68. Ng KW, et al. 2019. eLife. 0.333333333333333. PubMed
  69. Lei Y, et al. 2021. Clin Transl Immunology. 10:e1231. PubMed
  70. Sam J, et al. 2020. Front Oncol. 10:575737. PubMed
  71. Dai X, et al. 2021. Molecular Cell. 81(11):2317-2331.e6. PubMed
  72. Gilardini Montani MS, et al. 2020. Br J Cancer. 123:298. PubMed
  73. Xu H, et al. 2010. J Immunol. 185:7340. PubMed
  74. Padet L, et al. 2014. Immunobiology. 219:687. PubMed
  75. Suzuki D, et al. 2020. Stem Cell Reports. 14:49. PubMed
  76. Zhou X, et al. 2022. J Nucl Med. 63:536. PubMed
  77. Hu Q, et al. 2021. Nat Biomed Eng. 5:1038. PubMed
  78. Lau P, et al. 2022. Cell Mol Immunol. :. PubMed
  79. Darga EP, et al. 2021. PLoS One. 16:e0260124. PubMed
  80. Zhang H, et al. 2021. Adv Sci (Weinh). 8:2003404. PubMed
  81. Liang YH, et al. 2021. J Biomed Sci. 28:75. PubMed
  82. Shen C, et al. 2021. BMC Med. 19:283. PubMed
  83. Kenty JH, et al. 2021. STAR Protocols. 2(3):100675. PubMed
  84. Zhang C, et al. 2020. Front Oncol. 0.944444444. PubMed
  85. Ye Y, et al. 2020. Genome Med. 0.557638889. PubMed
  86. Tsukamoto M, et al. 2019. Cancer Sci. 110:310. PubMed
  87. Li CY, et al. 2022. Int J Mol Sci. 23:. PubMed
  88. Wang H, et al. 2022. J Cancer. 13:2126. PubMed
RRID
AB_940366 (BioLegend Cat. No. 329705) AB_940368 (BioLegend Cat. No. 329706)

Antigen Details

Distribution

T cells, B cells, NK cells, monocytes/macrophages, granulocytes and dendritic cells

Function
CD274 is involved in the costimulatory signal, essential for T lymphocyte proliferation and production of IL-10 and IFN-γ, in an IL-2-dependent and a PD-1-CD1-independent manner. Its interaction with PD-1-CD1 inhibits T-cell proliferation and cytokine production.
Ligand/Receptor
PD-1 (PDCD1)
Cell Type
B cells, Dendritic cells, Fibroblasts, Granulocytes, Macrophages, Monocytes, NK cells, T cells
Biology Area
Cancer Biomarkers, Costimulatory Molecules, Immunology
Molecular Family
Adhesion Molecules, CD Molecules, Immune Checkpoint Receptors
Antigen References

1. Sharpe A, et al. 2007. Nat. Immunol. 8:239.

Gene ID
29126 View all products for this Gene ID
UniProt
View information about CD274 on UniProt.org

联系我们

TEL：021-34661275 　点击拨打热线